IMPROVEMENT IN THE HAEMOSTATIC DEFECT OF URAEMIA AFTER TREATMENT WITH RECOMBINANT HUMAN ERYTHROPOIETIN

Marco Moia, Laura Vizzotto, Marco Cattaneo, Pier Mannuccio Mannucci, Stefano Casati, Claudio Ponticelli

Research output: Contribution to journalArticle

198 Citations (Scopus)

Abstract

Patients with uraemia have a defect of primary haemostasis expressed as long skin bleeding times and reduced platelet adhesion to the arterial subendothelium. Transfusion of red cells shortens the bleeding time and stops bleeding symptoms in uraemia. This study investigated whether the efficacy of recombinant human erythropoietin in correcting anaemia and the improvement in haemostasis are correlated. Recombinant human erythropoietin was given to seven consecutive patients with chronic uraemia, a history of bleeding, severe anaemia (haematocrit below 23%), and long bleeding times (above 19 min). The progressive rise in haematocrit induced by increasing doses of recombinant human erythropoietin was paralleled by a pronounced shortening of the bleeding time. Platelet adhesion to the subendothelium of human umbilical arteries, very low before the study, increased greatly in all patients and became normal in six. None of the patients bled during the study period.

Original languageEnglish
Pages (from-to)1227-1229
Number of pages3
JournalLancet
Volume330
Issue number8570
DOIs
Publication statusPublished - Nov 28 1987

Fingerprint

Bleeding Time
Uremia
Hemostatics
Erythropoietin
Hemostasis
Hematocrit
Anemia
Blood Platelets
Hemorrhage
Umbilical Arteries
Therapeutics
Skin

ASJC Scopus subject areas

  • Medicine(all)

Cite this

IMPROVEMENT IN THE HAEMOSTATIC DEFECT OF URAEMIA AFTER TREATMENT WITH RECOMBINANT HUMAN ERYTHROPOIETIN. / Moia, Marco; Vizzotto, Laura; Cattaneo, Marco; Mannuccio Mannucci, Pier; Casati, Stefano; Ponticelli, Claudio.

In: Lancet, Vol. 330, No. 8570, 28.11.1987, p. 1227-1229.

Research output: Contribution to journalArticle

Moia, Marco ; Vizzotto, Laura ; Cattaneo, Marco ; Mannuccio Mannucci, Pier ; Casati, Stefano ; Ponticelli, Claudio. / IMPROVEMENT IN THE HAEMOSTATIC DEFECT OF URAEMIA AFTER TREATMENT WITH RECOMBINANT HUMAN ERYTHROPOIETIN. In: Lancet. 1987 ; Vol. 330, No. 8570. pp. 1227-1229.
@article{bb4f0cc11ee5424d9ec6b2d0c3675a29,
title = "IMPROVEMENT IN THE HAEMOSTATIC DEFECT OF URAEMIA AFTER TREATMENT WITH RECOMBINANT HUMAN ERYTHROPOIETIN",
abstract = "Patients with uraemia have a defect of primary haemostasis expressed as long skin bleeding times and reduced platelet adhesion to the arterial subendothelium. Transfusion of red cells shortens the bleeding time and stops bleeding symptoms in uraemia. This study investigated whether the efficacy of recombinant human erythropoietin in correcting anaemia and the improvement in haemostasis are correlated. Recombinant human erythropoietin was given to seven consecutive patients with chronic uraemia, a history of bleeding, severe anaemia (haematocrit below 23{\%}), and long bleeding times (above 19 min). The progressive rise in haematocrit induced by increasing doses of recombinant human erythropoietin was paralleled by a pronounced shortening of the bleeding time. Platelet adhesion to the subendothelium of human umbilical arteries, very low before the study, increased greatly in all patients and became normal in six. None of the patients bled during the study period.",
author = "Marco Moia and Laura Vizzotto and Marco Cattaneo and {Mannuccio Mannucci}, Pier and Stefano Casati and Claudio Ponticelli",
year = "1987",
month = "11",
day = "28",
doi = "10.1016/S0140-6736(87)91849-6",
language = "English",
volume = "330",
pages = "1227--1229",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Lancet Publishing Group",
number = "8570",

}

TY - JOUR

T1 - IMPROVEMENT IN THE HAEMOSTATIC DEFECT OF URAEMIA AFTER TREATMENT WITH RECOMBINANT HUMAN ERYTHROPOIETIN

AU - Moia, Marco

AU - Vizzotto, Laura

AU - Cattaneo, Marco

AU - Mannuccio Mannucci, Pier

AU - Casati, Stefano

AU - Ponticelli, Claudio

PY - 1987/11/28

Y1 - 1987/11/28

N2 - Patients with uraemia have a defect of primary haemostasis expressed as long skin bleeding times and reduced platelet adhesion to the arterial subendothelium. Transfusion of red cells shortens the bleeding time and stops bleeding symptoms in uraemia. This study investigated whether the efficacy of recombinant human erythropoietin in correcting anaemia and the improvement in haemostasis are correlated. Recombinant human erythropoietin was given to seven consecutive patients with chronic uraemia, a history of bleeding, severe anaemia (haematocrit below 23%), and long bleeding times (above 19 min). The progressive rise in haematocrit induced by increasing doses of recombinant human erythropoietin was paralleled by a pronounced shortening of the bleeding time. Platelet adhesion to the subendothelium of human umbilical arteries, very low before the study, increased greatly in all patients and became normal in six. None of the patients bled during the study period.

AB - Patients with uraemia have a defect of primary haemostasis expressed as long skin bleeding times and reduced platelet adhesion to the arterial subendothelium. Transfusion of red cells shortens the bleeding time and stops bleeding symptoms in uraemia. This study investigated whether the efficacy of recombinant human erythropoietin in correcting anaemia and the improvement in haemostasis are correlated. Recombinant human erythropoietin was given to seven consecutive patients with chronic uraemia, a history of bleeding, severe anaemia (haematocrit below 23%), and long bleeding times (above 19 min). The progressive rise in haematocrit induced by increasing doses of recombinant human erythropoietin was paralleled by a pronounced shortening of the bleeding time. Platelet adhesion to the subendothelium of human umbilical arteries, very low before the study, increased greatly in all patients and became normal in six. None of the patients bled during the study period.

UR - http://www.scopus.com/inward/record.url?scp=0023276340&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023276340&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(87)91849-6

DO - 10.1016/S0140-6736(87)91849-6

M3 - Article

VL - 330

SP - 1227

EP - 1229

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 8570

ER -